Verrica Pharmaceuticals
VRCA49
$1.81arrow_drop_down6.70%-$0.13
Penny Stock
VRCA49
$1.81
arrow_drop_down6.70%Performance History
| Key Stats | |
|---|---|
| Open | $1.95 |
| Prev. Close | $1.94 |
| EPS | -1.89 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $77.23M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 1.81 | 1.95 |
| 52 Week Range | 1.77 | 11.41 |
| Ratios | |
|---|---|
| EPS | -1.89 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
••
About Verrica Pharmaceuticals (VRCA)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Ted White
- Headquarters
- West Chester
- Employees
- 22
- Exchange
- NASDAQ
Keep an eye on Verrica Pharmaceuticals
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is Verrica Pharmaceuticals 's (VRCA) price per share?
The current price per share for Verrica Pharmaceuticals (VRCA) is $1.81. The stock has seen a price change of -$0.13 recently, indicating a -6.7% change. This reflects the stock's recent market performance and investor sentiment.
help
What is the 52-week high and low for Verrica Pharmaceuticals (VRCA)?
For Verrica Pharmaceuticals (VRCA), the 52-week high is $11.41, which is 530.39% from the current price. The 52-week low is $1.77, the current price is 2.26% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help
Is Verrica Pharmaceuticals (VRCA) a growth stock?
Verrica Pharmaceuticals (VRCA) has shown an average price growth of 0.41% over the past three years. It has received a score of 29 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Verrica Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help
What is Verrica Pharmaceuticals (VRCA) stock price performance year to date (YTD)?
As of the latest data, Verrica Pharmaceuticals (VRCA) has a year-to-date price change of -73.42%. Over the past month, the stock has experienced a price change of -36.04%. Over the last three months, the change has been -74.9%. Over the past six months, the figure is -63.51%. Looking at a longer horizon, the five-year price change stands at -86.83%.
help
Is Verrica Pharmaceuticals (VRCA) a profitable company?
Verrica Pharmaceuticals (VRCA) has a net income of -$67M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 77.28% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -293.72% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $5.12M, although specific revenue growth data is currently not available. The gross profit is $3.96M. Operating income is noted at -$63.22M. Furthermore, the EBITDA is -$77.52M.
help
What is the market capitalization of Verrica Pharmaceuticals (VRCA)?
Verrica Pharmaceuticals (VRCA) has a market capitalization of $77.23M. The average daily trading volume is 482.32K, indicating the stock's liquidity and investor engagement.
News
VERRICA PHARMACEUTICALS
YCANTH
VP-315
COMMON WARTS
BASAL CELL CARCINOMA
8/14/2024Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results
HEALTH
LAW & LEGAL ISSUES
PRODUCT / SERVICES ANNOUNCEMENT
7/1/2024Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
HEALTH
CLINICAL STUDY
5/15/2024Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
NEWS
PRICE TARGET
MARKETS
TRADING IDEAS
5/14/2024Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
5/13/2024
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
EARNINGS RELEASES AND OPERATING RESULTS
5/13/2024Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results